I use observational data to explore the optimal treatment of multiple sclerosis, presently focussing on disease-modifying therapies.

I am also interested in improving data breadth and depth in registries through automating data extraction from electronic healthcare records; using non-conventional MRI to examine differential tissue vulnerability in multiple sclerosis; and help run phase II remyelination trials in the United Kingdom.